Nemaura Medical Inc. (NMRD) Social Stream

Featured Post From StockTwits About NMRD

$NMRD July 2021
Nasdaq: NMRD
We developed the world’s first Daily-Wear non-invasive
Continuous Glucose Monitor (CGM) – A Class 2b CE
approved Medical Device.
Launched: sugarBEAT® and BEAT®diabetes, supporting
Diabetes prevention, management and reversal.
Planned Launch in 2021: Mass Market consumer metabolic
health App & Glucose Sensor Kit

There are over 463 million people living with diabetes worldwide,
and over $760 Billion was spent in the US alone in 2019 for
diabetes related healthcare expenditure1

Total Addressable Market
UK
4.8 million people with diabetes8
One person diagnosed every 2
minutes
Germany
9.5 million have diabetes9.
4.5 million of these 9.5 million are
undiagnosed and, as a result, may
be particularly at risk.
U.S.
34.2 million have diabetes6
88 million people have prediabetes
28,000 people diagnosed with diabetes EVERY WEEK
in the U.S. alone7 in a market worth nearly $150B
https://nemauramedical.com/wp-content/uploads/2021/07/NMRD-Corporate-Deck-July-2021-1.2.pdf